On the 31 May 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,466 million and NAV per share was SEK 36.44. Return on NAV* in the month was -0.34%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 3.66 | 10.0% |
| Prokarium | 50% | 277 | 2.91 | 8.0% |
| Empros Pharma | 79% | 204 | 2.15 | 5.9% |
| KAHR Medical | 34% | 199 | 2.09 | 5.7% |
| Xspray Pharma | 17% | 198 | 2.08 | 5.7% |
| Atrogi | 44% | 197 | 2.07 | 5.7% |
| Bonsai Biotherapeutics | 100% | 158 | 1.66 | 4.6% |
| Microbiotica | 10% | 124 | 1.31 | 3.6% |
| Xintela | 60% | 110 | 1.16 | 3.2% |
| AnaCardio | 13% | 79 | 0.83 | 2.3% |
| Mendus | 23% | 75 | 0.79 | 2.2% |
| Geneos Therapeutics | 12% | 66 | 0.70 | 1.9% |
| EpiEndo Pharmaceuticals | 9% | 53 | 0.56 | 1.5% |
| Vitara Biomedical | 11% | 52 | 0.55 | 1.5% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.35 | 1.0% |
| Egetis Therapeutics | 1% | 29 | 0.30 | 0.8% |
| Amarna Therapeutics | 58% | 11 | 0.11 | 0.3% |
| Strike Pharma | 18% | 11 | 0.11 | 0.3% |
| Total | 2,225 | 23.40 | 64.2% | |
| Commercial Growth | ||||
| Symcel | 30% | 204 | 2.15 | 5.9% |
| NorthX Biologics | 61% | 202 | 2.12 | 5.8% |
| Chromafora | 28% | 137 | 1.45 | 4.0% |
| Nanologica | 50% | 104 | 1.09 | 3.0% |
| Frontier Biosolutions | 2% | 26 | 0.27 | 0.7% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 673 | 7.08 | 19.4% | |
| Assets related to Portfolio companies | 211 | 2.22 | 6.1% | |
| Other assets and liabilities | 356 | 3.74 | 10.3% | |
| Net Asset Value | 3,466 | 36.44 | 100.0% | |
* Following the bonus issue of 11,888,785 shares conducted in May, which will be followed by a cancellation of 8,412,578 shares to be approved in June, the return for the month is calculated on total NAV instead of as previously NAV per share.